Early impact therapy with ceftazidime-avibactam via rapid diagnostics versus standard of care antibiotics and diagnostics in patients with bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales - RAPID

ADVANCE ID0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•a) At risk of bloodstream infections, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales; OR,
•b) whose blood culture bottles growing Gram negative bacilli; OR,
•c) who are suspected to have hospital-acquired pneumonia or ventilator-associated pneumonia and whose respiratory samples show Gram negative bacteria on Gram stain

•a) Refractory shock or comorbid condition such that patient not expected to survive more than 48 hours; OR,
•b) where the bloodstream infection is thought to be related to a vascular catheter and the catheter is unable to be removed; OR,
•c) treatment is not with the intent to cure the infection; OR,
•d) patients previously randomised in this trial within the last 60 days.

发起方

ADVANCE ID